

Marie Christine BÃ©nÃ©

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5539622/publications.pdf>

Version: 2024-02-01

153
papers

5,199
citations

168829

31
h-index

107981

68
g-index

156
all docs

156
docs citations

156
times ranked

6428
citing authors

#	ARTICLE	IF	CITATIONS
1	Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues” Recommendations from the European <scp>LeukemiaNet</scp>. Cytometry Part B - Clinical Cytometry, 2023, 104, 15-26.	0.7	16
2	Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European <scp>LeukemiaNet</scp> International <scp>MDS&Flow</scp> Cytometry Working Group. Cytometry Part B - Clinical Cytometry, 2023, 104, 77-86.	0.7	18
3	Letter to the editor with regard to the article entitled “Automated leukocyte parameters are useful in the assessment of myelodysplastic syndromes”. Cytometry Part B - Clinical Cytometry, 2022, 102, 76-76.	0.7	0
4	Effect of DDAVP on Platelet Activation and Platelet-Derived Microparticle Generation. Hamostaseologie, 2022, 42, 185-192.	0.9	3
5	Post-SARS-CoV-2 vaccination specific antibody decrease : Let's get the half-full glass perspective. Journal of Infection, 2022, 84, 94-118.	1.7	2
6	Interference in platelet count due to microspherocytosis related to extensive burn injury. International Journal of Laboratory Hematology, 2022, 44, 57-58.	0.7	0
7	Safety and antibody response after one and/or two doses of BNT162b2 Anti&SARS&CoV&E2 mRNA vaccine in patients treated by CAR T cells therapy. British Journal of Haematology, 2022, 196, 360-362.	1.2	24
8	In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study. Blood Advances, 2022, 6, 1804-1812.	2.5	14
9	Hemophagocytic lymphohistiocytosis, what about hair?. American Journal of Hematology, 2022, 97, 508-509.	2.0	0
10	Interest of a third dose of BNT162b2 anti&SARS&CoV&E2 messenger RNA vaccine after allotransplant. British Journal of Haematology, 2022, 196, .	1.2	21
11	Humoral response to mRNA anti"COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia. Blood Advances, 2022, 6, 207-211.	2.5	38
12	Molecular Signature of ¹⁸F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study. Journal of Nuclear Medicine, 2022, 63, 1008-1013.	2.8	4
13	Unsupervised cluster analysis and subset characterization of abnormal erythropoiesis using the bioinformatic <scp>Flow&Self</scp> Organizing Maps algorithm. Cytometry Part B - Clinical Cytometry, 2022, 102, 134-142.	0.7	5
14	Anti&SARS&CoV&E2 vaccines in recipient and/or donor before allotransplant. EJHaem, 2022, , .	0.4	4
15	B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 279.e1-279.e4.	0.6	10
16	A series of case studies illustrating the role of flow cytometry in the diagnostic work&up of myelodysplastic syndromes. Cytometry Part B - Clinical Cytometry, 2022, , .	0.7	5
17	Suffering neutrophils« where is the enemy?. International Journal of Laboratory Hematology, 2022, 44, 806-807.	0.7	0
18	SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine. Vaccines, 2022, 10, 448.	2.1	24

#	ARTICLE	IF	CITATIONS
19	Mixed Phenotype/Lineage Leukemia: Has Anything Changed for 2021 on Diagnosis, Classification, and Treatment?. <i>Current Oncology Reports</i> , 2022, 24, 1015-1022.	1.8	8
20	Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party. <i>HemaSphere</i> , 2022, 6, e676.	1.2	35
21	Lineage switch and relapse in sanctuary site: Some lessons to learn about plasticity in <i>KMT2A</i> acute leukemia. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29683.	0.8	0
22	Effectiveness of a third dose of BNT162b2 anti-SARS-CoV-2 mRNA vaccine over a 6-month follow-up period in allogeneic hematopoietic stem cells recipients. <i>Hematological Oncology</i> , 2022, 40, 1097-1099.	0.8	8
23	Dramatic Recovery after Etoposide Phosphate Infusion for Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome following Treatment with Tisagenlecleucel in a Young Patient with Relapsed Acute Lymphoblastic Leukemia: A Case Report. <i>Acta Haematologica</i> , 2022, 145, 537-541.	0.7	5
24	Impact on outcomes of mixed chimerism of bone marrow CD34+ sorted cells after matched or haploidentical allogeneic stem cell transplantation for myeloid malignancies. <i>Bone Marrow Transplantation</i> , 2022, 57, 1435-1441.	1.3	2
25	Fluctuating plasmacytosis in an immunocompetent woman leading a diagnosis of plasmablastic lymphoma. <i>Annals of Hematology</i> , 2021, 100, 285-287.	0.8	1
26	Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. <i>Acta Oncologica</i> , 2021, 60, 466-474.	0.8	4
27	Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study. <i>Leukemia</i> , 2021, 35, 1291-1300.	3.3	5
28	Flow cytometry for platelets, EDTA or not EDTA: what is the answer?. <i>Platelets</i> , 2021, 32, 144-145.	1.1	0
29	Therapeutic targets in childhood acute lymphoblastic leukemia: what about HER2/neu?. <i>Hematological Oncology</i> , 2021, 39, 270-272.	0.8	1
30	Automated Early Detection of Myelodysplastic Syndrome within the General Population Using the Research Parameters of Beckman-Coulter DxH 800 Hematology Analyzer. <i>Cancers</i> , 2021, 13, 389.	1.7	11
31	Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 629.	1.7	23
32	Fortuitous discovery of an NPM1 mutation in a myelodysplastic syndrome. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1258-1259.	0.7	0
33	Conventional chemotherapy for acute myeloid leukemia in older adults: Impact on nutritional, cognitive, and functional status. <i>European Journal of Haematology</i> , 2021, 106, 859-867.	1.1	2
34	Unsupervised flow cytometry analysis in hematological malignancies: A new paradigm. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 54-64.	0.7	13
35	Issue Highlights-September 2021. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 537-540.	0.7	0
36	Platelet features allow to differentiate immune thrombocytopenia from inherited thrombocytopenia. <i>Annals of Hematology</i> , 2021, 100, 2677-2682.	0.8	5

#	ARTICLE	IF	CITATIONS
37	The Plasmacytoid Dendritic Cell CD123+ Compartment in Acute Leukemia with or without RUNX1 Mutation: High Inter-Patient Variability Disclosed by Immunophenotypic Unsupervised Analysis and Clustering. <i>Hemato</i> , 2021, 2, 572-585.	0.2	2
38	Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant. <i>JAMA Network Open</i> , 2021, 4, e2126344.	2.8	55
39	Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1378-1390.	5.1	84
40	Occupational pesticide exposure increases risk of acute myeloid leukemia: a meta-analysis of caseâ€“control studies including 3,955 cases and 9,948 controls. <i>Scientific Reports</i> , 2021, 11, 2007.	1.6	11
41	Definition of Erythroid Differentiation Subsets in Normal Human Bone Marrow Using FlowSOM Unsupervised Cluster Analysis of Flow Cytometry Data. <i>HemaSphere</i> , 2021, 5, e512.	1.2	7
42	2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. <i>Blood</i> , 2021, 138, 2753-2767.	0.6	305
43	Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 3911-3911.	0.6	1
44	Interest of a Third Dose of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients. <i>Blood</i> , 2021, 138, 3908-3908.	0.6	0
45	Peripheral Levels of Monocytic Myeloid-Derived Suppressive Cells at Diagnosis Predict Survivals in AML Patients Eligible for Intensive Chemotherapy. <i>Blood</i> , 2021, 138, 3465-3465.	0.6	0
46	Low-Dose Pesticides Alter Primary Human Bone Marrow Mesenchymal Stem/Stromal Cells through ALDH2 Inhibition. <i>Cancers</i> , 2021, 13, 5699.	1.7	6
47	Antibody Response after One and/or Two Doses of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Patients Treated By CAR T-Cells Therapy. <i>Blood</i> , 2021, 138, 254-254.	0.6	1
48	Comparable Outcomes Among Adult Patients Allotransplanted for Myelodysplastic Syndrome Using Haploidentical, Matched Unrelated or Matched Sibling Donors: A Single-Center Study. <i>Blood</i> , 2021, 138, 4914-4914.	0.6	0
49	CPX 351 As First Line Treatment in Higher Risk MDS. a Phase II Trial By the GFM. <i>Blood</i> , 2021, 138, 243-243.	0.6	18
50	Single Capture High Throughput Sequencing Assay for Combined V(D)J Clonality Analysis and Oncogene Mutations in the Diagnosis of T and B Lymphoid Malignancies. <i>Blood</i> , 2021, 138, 2404-2404.	0.6	0
51	A Prospective Phase 2 Study Testing High Dose Post-Transplant Cyclophosphamide As Sole Ghvd Prophylaxis after Matched Allotransplant Using Baltimore-Based Reduced-Intensity Conditioning Regimens and PBSC As Source of Graft. <i>Blood</i> , 2021, 138, 1812-1812.	0.6	1
52	Sars-Cov-2 T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients Following Two Doses of BNT162b2 Vaccine. <i>Blood</i> , 2021, 138, 2895-2895.	0.6	0
53	Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells. <i>Oncogene</i> , 2020, 39, 1198-1212.	2.6	32
54	Use of von Willebrand Factor Concentrate in Inherited von Willebrand Disease: How Often Is It Useful to Add Factor VIII?. <i>Transfusion Medicine Reviews</i> , 2020, 34, 128-129.	0.9	1

#	ARTICLE	IF	CITATIONS
73	Serum albumin or body mass index: Which prognostic factor for survival in patients with acute myeloblastic leukaemia?. <i>Hematological Oncology</i> , 2019, 37, 80-84.	0.8	15
74	An RÃ©Derived FlowSOM Process to Analyze Unsupervised Clustering of Normal and Malignant Human Bone Marrow Classical Flow Cytometry Data. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2019, 95, 1191-1197.	1.1	28
75	Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia. <i>Leukemia</i> , 2019, 33, 1814-1816.	3.3	10
76	The wonderful story of monoclonal antibodies. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 8-14.	0.7	2
77	Multiparameter flow cytometry applications in the diagnosis of mixed phenotype acute leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 183-194.	0.7	33
78	Morphological and Immunophenotypic Clues to the WHO Categories of Acute Myeloid Leukaemia. <i>Acta Haematologica</i> , 2019, 141, 232-244.	0.7	57
79	Early (Day 15 Post Diagnosis) Peripheral Blood Assessment of Measurable Residual Disease in Flow Cytometry is a Strong Predictor of Outcome in Childhood BÃ©Lineage Lymphoblastic Leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 128-133.	0.7	6
80	Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome after T CellÃ©Replete Haploidentical Hematopoietic Stem Cell Transplantation with Posttransplant Cyclophosphamide. <i>Journal of Immunology</i> , 2019, 202, 2141-2152.	0.4	32
81	How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?. <i>Blood Advances</i> , 2019, 3, 4238-4251.	2.5	72
82	Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes. <i>Blood Advances</i> , 2019, 3, 4271-4279.	2.5	19
83	Innovation in Flow Cytometry Analysis: A New Paradigm Delineating Normal or Diseased Bone Marrow Subsets Through Machine Learning. <i>HemaSphere</i> , 2019, 3, e173.	1.2	21
84	CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation. <i>British Journal of Haematology</i> , 2019, 184, 625-633.	1.2	10
85	Bendamustine plus rituximab in newlyÃ©diagnosed WaldenstrÃ©m macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO). <i>British Journal of Haematology</i> , 2019, 186, 146-149.	1.2	51
86	Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 906-911.	2.0	6
87	A new case of heterozygous variant of the <i>GP</i>1<i>BB</i> gene responsible for macrothrombocytopenia. <i>British Journal of Haematology</i> , 2019, 186, 157-159.	1.2	4
88	Bleeding risk for patients with haemophilia under antithrombotic therapy. Results of the French multicentric study <i>ERHEA</i>. <i>British Journal of Haematology</i> , 2019, 185, 764-767.	1.2	9
89	Comparison of the Performance of Surface Alone or Surface Plus Cytoplasmic Approaches for the Assessment of Minimal Residual Disease in Multiparameter Flow Cytometry in Multiple Myeloma. <i>Blood</i> , 2019, 134, 1799-1799.	0.6	2
90	Clinical and Biological Characteristics and Outcomes of Richter Transformation : A French Multicenter Study from the Filo Group. <i>Blood</i> , 2019, 134, 4112-4112.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Prognostic Value of Lymphopenia and Lymphocytosis after Peripheral Blood Haplo-Identical Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 3319-3319.	0.6	0
92	Profound Lymphopenia at the Time of ATG Administration Is Not Predictive of Survivals after Allograft Using Purine Analogue/Busulfan-Based Conditioning Regimen. <i>Blood</i> , 2019, 134, 1985-1985.	0.6	0
93	Multicentric Real Life Evaluation of the Impact of Next-Generation Sequencing on the Clinical Management of Chronic Myeloid Malignancies. <i>Blood</i> , 2019, 134, 5771-5771.	0.6	0
94	<sc>CD200</sc> expression in flow cytometry helps to distinguish mantle cell lymphoma from other <sc>CD</sc>5â€positive <sc>B</sc>â€cell neoplasms. <i>Hematological Oncology</i> , 2018, 36, 607-609.	0.8	7
95	Rituximab for second desensitization in patients with rebound of donor-specific anti-HLA antibodies before T-replete haplo-transplant using high-dose post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2018, 53, 1044-1047.	1.3	6
96	Emergence and evolution of <i>TP53</i> mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide. <i>Haematologica</i> , 2018, 103, e143-e146.	1.7	41
97	Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. <i>Blood</i> , 2018, 131, 1275-1291.	0.6	796
98	A new mutation of <i><sc>ANO</sc></i>6 in two familial cases of Scott syndrome. <i>British Journal of Haematology</i> , 2018, 180, 750-752.	1.2	15
99	R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. <i>Blood</i> , 2018, 131, 174-181.	0.6	121
100	Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple TP53 alterations. <i>Haematologica</i> , 2018, 103, e13-e16.	1.7	18
101	Panel proposal for the immunophenotypic diagnosis of hematological malignancies. A collaborative consensus from the groupe d'Etude Immunologique des LeucÃ©mies (GEIL). <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 542-547.	0.7	10
102	Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia. <i>Hematological Oncology</i> , 2018, 36, 422-428.	0.8	18
103	Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3203-3210.	0.8	32
104	A novel complete blood countâ€based score to screen for myelodysplastic syndrome in cytopenic patients. <i>British Journal of Haematology</i> , 2018, 183, 736-746.	1.2	15
105	Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts. <i>Haematologica</i> , 2018, 103, 1593-1603.	1.7	49
106	Evaluation of minimal residual disease in childhood <sc>ALL</sc>. <i>International Journal of Laboratory Hematology</i> , 2018, 40, 104-108.	0.7	3
107	Impact on early outcomes and immune reconstitution of high-dose post-transplant cyclophosphamide vs anti-thymocyte globulin after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation. <i>Oncotarget</i> , 2018, 9, 11451-11464.	0.8	46
108	Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies. <i>Oncotarget</i> , 2018, 9, 33528-33535.	0.8	17

#	ARTICLE	IF	CITATIONS
109	Cytométrie en flux. , 2018, , 27-39.		0
110	Maladie résiduelle moléculaire. , 2018, , 301-306.		0
111	Poor Prognosis Associated with Gains of CCND1 in Mantle Cell Lymphoma Treated By First Line Immuno-Chemotherapy â€” a Study By the Lysa Group. Blood, 2018, 132, 4099-4099.	0.6	0
112	Correlations between p16 Protein Expression and Genomic Profile in Mantle Cell Lymphoma and Impact on Survival, a Lyma-Genomic Project Conducted on Behalf of the Lysa Group. Blood, 2018, 132, 2846-2846.	0.6	0
113	Major impact of an early bone marrow checkpoint (day 21) for minimal residual disease in flow cytometry in childhood acute lymphoblastic leukemia. Hematological Oncology, 2017, 35, 237-243.	0.8	4
114	Impact of body surface area on patientsâ€™ outcome in younger adults with acute myeloid leukemia. European Journal of Haematology, 2017, 98, 443-449.	1.1	6
115	Research in morphology and flow cytometry is at the heart of hematology. Haematologica, 2017, 102, 421-422.	1.7	2
116	Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?. European Journal of Haematology, 2017, 99, 60-69.	1.1	5
117	Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group. Haematologica, 2017, 102, 308-319.	1.7	74
118	Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. New England Journal of Medicine, 2017, 377, 1250-1260.	13.9	313
119	Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia. Blood, 2017, 130, 1832-1844.	0.6	66
120	Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget, 2017, 8, 73483-73500.	0.8	153
121	Innovation in hematology: morphology and flow cytometry at the crossroads. Haematologica, 2016, 101, 394-395.	1.7	1
122	CD180 expression in B-cell lymphomas: A multicenter GEIL study. Cytometry Part B - Clinical Cytometry, 2016, 90, 462-466.	0.7	16
123	CD38 Expression in B-Lineage Acute Lymphoblastic Leukemia, a Possible Target for Immunotherapy. Blood, 2016, 128, 5268-5268.	0.6	5
124	Engraftment of Donor Cells after Allogeneic Stem Cell Transplantation: Comparison and Impact of Chimerism in Whole Blood and Peripheral CD3+ T-Cells. Blood, 2016, 128, 5866-5866.	0.6	0
125	Comparative Value of the Assessment of Minimal Residual Disease in Peripheral Blood at Days 8 and 15 By Flow Cytometry in Childhood Acute Lymphoblastic Leukemia. Blood, 2016, 128, 5270-5270.	0.6	1
126	The closely related rare and severe acute myeloid leukemias carrying EVI1 or PRDM16 rearrangements share singular biological features. Haematologica, 2015, 100, e114-e115.	1.7	7

#	ARTICLE	IF	CITATIONS
127	The routine leukocyte differential flow cytometry <sc>H</sc>emato<sc>F</sc>lowâ„¢ method: A new flagging system for automatic validation. <i>Cytometry Part B - Clinical Cytometry</i> , 2015, 88, 375-384.	0.7	15
128	Leukemia diagnosis: today and tomorrow. <i>European Journal of Haematology</i> , 2015, 95, 365-373.	1.1	21
129	Detection of phosphatidyl serine on activated platelets' surface by flow cytometry in whole blood: a simpler test for the diagnosis of Scott syndrome. <i>British Journal of Haematology</i> , 2015, 171, 290-292.	1.2	16
130	Place de la cytométrie en flux dans le diagnostic et le suivi des leucémies aiguës. <i>Revue Francophone Des Laboratoires</i> , 2015, 2015, 35-41.	0.0	0
131	Acute Leukemias of Ambiguous Origin. <i>American Journal of Clinical Pathology</i> , 2015, 144, 361-376.	0.4	46
132	Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study. <i>Haematologica</i> , 2015, 100, e128-e131.	1.7	26
133	Safety and Long-Term Efficacy of Maintenance Therapy with Alternating Azacytidine (AZA) and Lenalidomide (Len) Cycles in Elderly (≥ 60) Fit Patients (Pts) with Poor Prognosis AML in First Complete Remission (CR) After LIA Induction. A Phase II Multicentric GOELAMS Trial. <i>Blood</i> , 2015, 126, 3787-3787.	0.6	1
134	First Line Chronic Lymphocytic Leukemia Immunochemotherapy for the Elderly Patients over 79 Years Is Feasible, and Achieves Good Results: A Filo Retrospective Study. <i>Blood</i> , 2015, 126, 4170-4170.	0.6	1
135	Allogeneic Stem Cell Transplantation for Primary or Secondary Myelofibrosis: A Retrospective Intent-to-Treat Analysis and Impact of Mutational Status and JAK1/2 Inhibitor Ruxolitinib Prescription in Patients Who Cannot Proceed to Transplantation. <i>Blood</i> , 2015, 126, 3218-3218.	0.6	0
136	Post-Transplant Cyclophosphamide (PTCY) Versus Anti-Thymoglobulin (ATG) As Part of the Gvhd Prophylaxis for Fludarabine/Clofarabine/Busulfan Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT): Influence on Early Outcomes. <i>Blood</i> , 2015, 126, 4339-4339.	0.6	0
137	Expansion of T or B Lymphocytes after Unrelated Cord Blood (UCB) Allogeneic Stem Cell Transplantation in Adults Correlates with CMV Reactivation and Is Associated with a Better Outcome. <i>Blood</i> , 2015, 126, 1947-1947.	0.6	0
138	Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group. <i>Haematologica</i> , 2014, 99, 46-53.	1.7	44
139	Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. <i>Blood</i> , 2014, 123, 3739-3749.	0.6	281
140	Morphology and immunophenotyping issues in the integrated diagnosis of hematologic disorders of elderly patients. <i>Haematologica</i> , 2014, 99, 951-953.	1.7	0
141	Flow cytometry thresholds of myeloperoxidase detection to discriminate between acute lymphoblastic or myeloblastic leukaemia. <i>British Journal of Haematology</i> , 2013, 161, 551-555.	1.2	38
142	Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. <i>Leukemia and Lymphoma</i> , 2013, 54, 472-475.	0.6	66
143	Validation of cell-based fluorescence assays: Practice guidelines from the ICSH and ICCS â€“ part V â€“ assay performance criteria. <i>Cytometry Part B - Clinical Cytometry</i> , 2013, 84, 315-323.	0.7	153
144	Comparable flow cytometry data can be obtained with two types of instruments, Canto II, and Navios. A GEL study. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2013, 83, 1066-1072.	1.1	36

#	ARTICLE	IF	CITATIONS
145	Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study. <i>Blood</i> , 2012, 119, 2943-2948.	0.6	45
146	Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study. <i>Blood</i> , 2012, 119, 2474-2477.	0.6	14
147	Acute leukemias of ambiguous lineage. <i>Seminars in Diagnostic Pathology</i> , 2012, 29, 12-18.	1.0	68
148	Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. <i>Blood</i> , 2011, 117, 3163-3171.	0.6	252
149	Four- and five-color flow cytometry analysis of leukocyte differentiation pathways in normal bone marrow: A reference document based on a systematic approach by the GTLLF and GEIL. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, 4-10.	0.7	36
150	Addition of Lomustine to Idarubicin and Cytarabine Improves the Outcome of Elderly Patients With De Novo Acute Myeloid Leukemia: A Report From the GOELAMS. <i>Journal of Clinical Oncology</i> , 2010, 28, 3028-3034.	0.8	36
151	Biphenotypic, bilineal, ambiguous or mixed lineage: strange leukemias!. <i>Haematologica</i> , 2009, 94, 891-893.	1.7	44
152	Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. <i>British Journal of Haematology</i> , 2009, 145, 624-636.	1.2	163
153	Clinical and biologic features of CD4+CD56+ malignancies. <i>Blood</i> , 2002, 99, 1556-1563.	0.6	404